literature

HIV mutation literature information.

High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.

PMID: 22739389 2012 AIDS (London, England)

Discussion: However, mutations found in combination with K65R in our study either have a minor effect on susceptibility to AZT or enhance susceptibility to AZT (eg.L74V, Y181C, M184V as well as K65R).

Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City.

PMID: 22592583 2012 Journal of acquired immune deficiency syndromes (1999)

4Method: ARV resistance was defined by mutations at the following positions: M41L, A62V, K65R, D67N, T69ins, K70R, L74VI, Y115F, F116Y, Q151M, M184VI, T210W, T215YF and K219QE for Nucleoside Reverse Transcriptase Inhibitors (NRTI), L100I, K101EP, K103NS, V106AM

HIV-1 drug resistance in antiretroviral-naive individuals with HIV-1-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam.

PMID: 22473024 2012 Antiviral therapy

Abstract: SDRMs were identified in 14/219 (6.4%) subjects; 8/14 were resistant to nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs; T69D, L74V, V75M, M184V/I and K219R), 5/14 to non-nucleoside reverse transcriptase inhibitors (NNRTIs; K103N, V106M, Y181C, Y188C and G190A), 1/14 to both NRTIs and NNRTIs (D67N and Y181C) and none to

PMID: 22359615 2012 PloS one

Table: L74V

Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.

PMID: 21972264 2012 Journal of the International Association of Physicians in AIDS Care (Chicago, Ill.

Abstract: Nucleoside reverse transcriptase inhibitor-associated mutation frequencies noted were M184V (n = 41; 91.1%); thymidine analogue mutations (TAMs; n = 20; 44.4%); >1 TAM (n = 9; 20%); TAM-2 pathway (n = 10; 22.2%); TAM-1 pathway (n = 7; 15.6%); TAM-1 and TAM-2 pathways (n = 3; 6.7%); K65R (n = 2; 4.4%); Q151M (n = 1; 2.2%); and L74V (n = 0; 0%).

HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

PMID: 21633285 2011 AIDS (London, England)

Result: Nineteen samples had major NRTI mutations, specifically K219E/Q (n=8), L74V (n=7), K70E (n=3), D67N (n=2) and L210W (n=1).

The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase.

PMID: 21646480 2011 Antimicrobial agents and chemotherapy

Abstract: Population sequencing of the entire reverse transcriptase (RT) gene identified L74V, F77L, and L214F mutations in the polymerase domain and K476N and V518I mutations in the RNase H domain.

Abstract: Single-genome sequencing analyses of the selected virus revealed a complex population of mutants that all contained L74V and L214F linked to other mutations, including ones not identified during population sequencing.

Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase.

PMID: 21859446 2011 Retrovirology

Introduction: Furthermore, N348I can compensate for the antagonism of thymidine analog mutations (TAMs) by the L74V, Y181C or M184V mutations.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

PMID: 22132100 2011 PloS one

Method: RT mutations were identified from the International AIDS Society USA Drug (IAS-USA) mutation tables, spring 2008 (http://www.iasusa.org/resistance_mutations): M41L, K65R, D67N, insertion 69, K70R/E, L74I/V, L100I, K103N, V106A/M, V108I, Q151M, Y181I/C, M184V, Y188C/L, G190A/S, L210W, T215Y/F,

PMID: 22180722 2011 Romanian biotechnological letters

Result: 19.5% of the patients presented L74V/I mutation that occur in patients with virologic failure while receiving non-TAM regimens and causes intermediate resistance to DDI and ABC, and a slight increase in susceptibility to AZT and TDF.

Browser Board

Co-occurred Entities

Filtrator